๐ The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect approximately 5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
keywords
author
๐ค Caly, Leon
๐ค Druce, Julian D
๐ค Catton, Mike G
๐ค Jans, David A
๐ค Wagstaff, Kylie M
year
โฐ 2020
journal
๐ Antiviral Res
issn
๐
volume
number
page
citedbycount
0
download
๐ [BibTeX]